62 related articles for article (PubMed ID: 28482130)
1.
Massmann A; Van Heukelom J; Green RC; Hajek C; Hickingbotham MR; Larson EA; Lu CY; Wu AC; Zoltick ES; Christensen KD; Schultz A
Pharmacogenomics; 2023 May; 24(7):399-409. PubMed ID: 37232094
[No Abstract] [Full Text] [Related]
2. Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.
Takehara I; Terashima H; Nakayama T; Yoshikado T; Yoshida M; Furihata K; Watanabe N; Maeda K; Ando O; Sugiyama Y; Kusuhara H
Pharm Res; 2017 Aug; 34(8):1601-1614. PubMed ID: 28550384
[TBL] [Abstract][Full Text] [Related]
3. Potential Drug Interactions Mediated by Renal Organic Anion Transporter OATP4C1.
Sato T; Mishima E; Mano N; Abe T; Yamaguchi H
J Pharmacol Exp Ther; 2017 Aug; 362(2):271-277. PubMed ID: 28550055
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.
Liu SG; Gao C; Zhang RD; Zhao XX; Cui L; Li WJ; Chen ZP; Yue ZX; Zhang YY; Wu MY; Wang JX; Li ZG; Zheng HY
Oncotarget; 2017 Jun; 8(23):37761-37772. PubMed ID: 28525903
[TBL] [Abstract][Full Text] [Related]
5. Analysis of National Pharmacovigilance Data Associated with Statin Use in Korea.
Kim H; Kim N; Lee DH; Kim HS
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):409-413. PubMed ID: 28500776
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study.
El-Nabarawi N; El-Wakd M; Salem M
Drug Des Devel Ther; 2017; 11():1383-1391. PubMed ID: 28496308
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin-Diltiazem Combination Induced Rhabdomyolysis Leading to Diagnosis of Hypothyroidism.
Ehelepola NDB; Sathkumara SMBY; Bandara HMPAGS; Kalupahana KLR
Case Rep Med; 2017; 2017():8383251. PubMed ID: 28487744
[TBL] [Abstract][Full Text] [Related]
8. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.
Wu X; Gong C; Weinstock J; Cheng J; Hu S; Venners SA; Hsu YH; Wu S; Zha X; Jiang S; Li Y; Pan F; Xu X
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):240S-247S. PubMed ID: 30336686
[TBL] [Abstract][Full Text] [Related]
9. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.
Cacabelos R; Naidoo V; Corzo L; Cacabelos N; Carril JC
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948113
[TBL] [Abstract][Full Text] [Related]
10. Genetic contribution to lipid target achievement with statin therapy: a prospective study.
Ruiz-Iruela C; Candás-Estébanez B; Pintó-Sala X; Baena-Díez N; Caixàs-Pedragós A; Güell-Miró R; Navarro-Badal R; Calmarza P; Puzo-Foncilla JL; Alía-Ramos P; Padró-Miquel A
Pharmacogenomics J; 2020 Jun; 20(3):494-504. PubMed ID: 31806882
[TBL] [Abstract][Full Text] [Related]
11. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
[TBL] [Abstract][Full Text] [Related]
12. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.
Kitzmiller JP; Luzum JA; Baldassarre D; Krauss RM; Medina MW
Pharmacogenet Genomics; 2014 Oct; 24(10):486-91. PubMed ID: 25051018
[TBL] [Abstract][Full Text] [Related]
13. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
[TBL] [Abstract][Full Text] [Related]
14. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
15. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
[TBL] [Abstract][Full Text] [Related]
16. Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin.
Kitzmiller JP; Luzum JA; Dauki A; Krauss RM; Medina MW
Clin Transl Sci; 2017 May; 10(3):172-177. PubMed ID: 28482130
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
